BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10082075)

  • 1. Safety profile of Lansoprazole: the US clinical trial experience.
    Freston JW; Rose PA; Heller CA; Haber M; Jennings D
    Drug Saf; 1999 Feb; 20(2):195-205. PubMed ID: 10082075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
    Brunner G; Arnold R; Hennig U; Fuchs W
    Aliment Pharmacol Ther; 1993; 7 Suppl 1():51-5, discussion 61-6. PubMed ID: 8490080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lansoprazole: an update of its place in the management of acid-related disorders.
    Matheson AJ; Jarvis B
    Drugs; 2001; 61(12):1801-33. PubMed ID: 11693467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
    Barradell LB; Faulds D; McTavish D
    Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid healing of gastric ulcers with lansoprazole.
    Bardhan KD; Ahlberg J; Hislop WS; Lindholmer C; Long RG; Morgan AG; Sjostedt S; Smith PM; Stig R; Wormsley KG
    Aliment Pharmacol Ther; 1994 Apr; 8(2):215-20. PubMed ID: 8038354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
    Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Robinson M; McFarland M; Sabesin S; Lehman GA; Castell D
    Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lansoprazole: a comprehensive review.
    Zimmermann AE; Katona BG
    Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group.
    Robinson M; Sahba B; Avner D; Jhala N; Greski-Rose PA; Jennings DE
    Aliment Pharmacol Ther; 1995 Feb; 9(1):25-31. PubMed ID: 7766740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
    Langtry HD; Wilde MI
    Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of long-term treatment with lansoprazole and omeprazole on serum gastrin and the fundic mucosa.
    Arroyo Villarino MT; Lanas Arbeloa A; Esteva Díaz F; Ortego Fernández de Retana J; Sainz Samitier R
    Rev Esp Enferm Dig; 1997 May; 89(5):347-56. PubMed ID: 9190140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
    Spencer CM; Faulds D
    Drugs; 1994 Sep; 48(3):404-30. PubMed ID: 7527761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children.
    Tolia V; Fitzgerald J; Hassall E; Huang B; Pilmer B; Kane R
    J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S300-7. PubMed ID: 12607790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group.
    Lanza F; Goff J; Scowcroft C; Jennings D; Greski-Rose P
    Am J Gastroenterol; 1994 Aug; 89(8):1191-200. PubMed ID: 8053433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton-pump inhibition for acid-related disease.
    Holt S
    South Med J; 1991 Sep; 84(9):1078-87. PubMed ID: 1653998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies.
    Berstad A; Hatlebakk JG
    Aliment Pharmacol Ther; 1993; 7 Suppl 1():34-6, discussion 61-6. PubMed ID: 8490077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of patients with Zollinger-Ellison syndrome.
    Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
    Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.
    Russo A; Dattilo M
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):312-9. PubMed ID: 9476183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine.
    Swarbrick ET; Gough AL; Foster CS; Christian J; Garrett AD; Langworthy CH
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):431-8. PubMed ID: 8804870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C
    Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of lansoprazole, omeprazole, and ranitidine for reducing preoperative gastric secretion in adult patients undergoing elective surgery.
    Nishina K; Mikawa K; Maekawa N; Takao Y; Shiga M; Obara H
    Anesth Analg; 1996 Apr; 82(4):832-6. PubMed ID: 8615506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.